The Ghost of Liquidity: Baichuan AI’s Pivot and the Echoes of Crypto’s Narrative Cycles

Tracing the liquidity ghost in the machine, I watch another founder burn the bridges of general-purpose ambition to chase a vertical oasis. Baichuan AI—once a flagbearer in China’s large language model (LLM) race—has retreated from the base-model battlefield into the walled garden of medical AI. Its co-founders have walked out; its valuation of ¥20 billion (≈$2.8B) now floats on hope rather than revenue. This is not a story about artificial intelligence alone. It is a story about capital, narrative, and the cyclical tragedy of pivoting too late—a rhythm I have seen etched into the ledgers of crypto since the Merge. The event itself is deceptively simple: Baichuan, founded by search-engine veteran Wang Xiaochuan, raised ¥5 billion in 2023 at a peak of LLM mania. Now it admits the general-purpose arms race is unwinnable and narrows its focus to healthcare—a sector with high barriers, long sales cycles, and deep regulatory entanglement. Two co-founders, Ru Liyun and others, have exited, signaling ideological fractures. The market interprets this as weakness; I interpret it as a macro signal of capital efficiency debates spilling over from crypto into AI. The ETF wave washed away the retail tide in crypto; the LLM wave is now washing away the generalists. Context: Baichuan’s original bet was on a foundational model—Baichuan-series—that ranked in China’s top ten in 2023 but slipped by 2024 as Qwen, DeepSeek, and Yi surged ahead. Maintaining a general LLM requires billions in compute (thousands of H100 GPUs, months of pre-training), a cost structure that mirrors Bitcoin mining’s energy intensity. In crypto, we saw miners capitulate post-halving; in AI, we see modelers capitulate post-scaling law. Baichuan’s pivot to healthcare is not a visionary leap but a survival move—one that mirrors Layer-2 rollups abandoning general-purpose execution for application-specific chains. Privacy eroded not by code, but by consensus; in both worlds, the consensus is that capital will no longer subsidize open-ended R&D. Core insight: The medical AI vertical, as Baichuan is targeting, requires a different kind of liquidity—not GPUs but regulatory credentials (NMPA class II/III certificates), hospital partnerships, and real-world data access. I quantify the mismatch: ¥5 billion can fund 18-24 months of development at burn rates typical for LLM startups (¥200M-300M per quarter on compute and talent). Once you subtract the cost of pivoting (redundant staff, contract penalties with cloud providers), the runway shrinks to 12-15 months. In crypto terms, this is like a Layer-1 project migrating to a sidechain with no bridging liquidity. The market cap of ¥200 billion implies a price-to-sales ratio of 4x based on hypothetical revenue—a fantasy when the company has zero disclosed medical AI revenue. My own work on modeling CBDC liquidity flows taught me to distrust any valuation that outpaces cash flows by more than 2x; here, the gap is infinite. Yet there is a hidden technical angle: Baichuan’s new medical model, M4, likely leverages retrieval-augmented generation (RAG) and fine-tuning on the existing Baichuan base, avoiding the cost of a full pretrain. This is analogous to zk-rollup operators upgrading their prover hardware rather than redesigning from scratch. But zk-proving costs remain absurdly high unless gas prices return to bull-market levels—similarly, M4’s inference cost per interaction may be too high for a free consumer-facing agent like "Bai Xiaoyi" without subsidy. The data-privacy requirements of healthcare (patient chat logs, diagnostic histories) demand zero-knowledge compliance layers—a technology I once championed in a CBDC memo that faced pushback from regulators. History rhymes in the ledger; Baichuan will face the same tension between utility and surveillance. Contrarian angle: The conventional narrative paints Baichuan’s pivot as a rational hedge—medical AI has a clear business model (hospital software subscriptions, drug RWE generation). I argue this is a decoupling fallacy. In crypto, the belief that DeFi yields were decoupled from centralized market risks was shattered by Terra. In AI, the belief that a vertical application can thrive without continuous base-model improvement is equally fragile. M4’s ceiling is defined by the general reasoning ability of its underlying model. If Baichuan stops iterating the base, within two years even open-source models like Llama 5 or Qwen 3 will outperform its domain-specific fine-tune. The result is a death spiral: the application becomes commoditized, and the only moat is regulatory—a slow, expensive moat to build. We sleepwalk into a digital panopticon where every pivot feels logical until the next bust. From my experience advising a Gulf central bank on CBDC design, I saw firsthand how bureaucratic inertia can strangle innovation. Baichuan’s CEO, Wang Xiaochuan, now shoulders the entire vision alone—a single-point-of-failure that crypto DAOs try to avoid but often replicate. The co-founders who left favored AI programming (code generation agents) and enterprise API services—both linear revenue streams that Baichuan is abandoning. In crypto, we call that "losing the developer mindshare." To replace them, Wang must recruit medical-domain leaders from hospitals or pharma, a talent pool that commands high salaries and has little tolerance for startup chaos. The ¥5 billion may cover salaries, but it cannot buy the decade-long trust required to sell to Chinese hospitals. Takeaway: Baichuan AI’s story is not an anomaly but a template. As capital rotates out of general-purpose AI into vertical applications, expect more "pivots" that mirror crypto’s cycle of narrative chasing—from DeFi to NFTs to GameFi to AI agents. Each pivot burns liquidity and erodes founding teams. The question I leave the reader with is this: when the next bull market arrives, will the ghost of a failed pivot still haunt the ledger, or will the tide of new capital wash away the memory? I have seen the answer in the Merge—it washes away nothing but the retail tide. The scars remain on the balance sheet, a permanent record of the time we mistook narrative for fundamentals.